Nasopharyngeal Haemophilus and local immune response during infant respiratory syncytial virus infection

Respiratory syncytial virus and the infant immune response.

Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment.

Respiratory syncytial virus (RSV) is the single most important cause of lower respiratory tract infection during infancy and early childhood. Once RSV infection is established, the host immune response includes the production of virus-neutralizing antibodies and T-cell-specific immunity. The humoral immune response normally results in the development of anti-RSV neutralizing-antibody titers, bu...

Immune responses and disease enhancement during respiratory syncytial virus infection.

Respiratory syncytial virus (RSV) is one of the commonest and most troublesome viruses of infancy. It causes most cases of bronchiolitis, which is associated with wheezing in later childhood. In primary infection, the peak of disease typically coincides with the development of specific T- and B-cell responses, which seem, in large part, to be responsible for disease. Animal models clearly show ...

Local immune response to respiratory syncytial virus infection is diminished in senescence-accelerated mice.

The effect of ageing on the local defence system against respiratory syncytial virus (RSV) infection was investigated using an aged mouse model of the senescence-accelerated mouse (SAM) strain P1. Following intranasal infection with RSV, SAM-P1 mice showed a marked loss in weight, with elevated virus growth in the lungs and prolonged virus shedding. The increased susceptibility to RSV infection...

Innate immune recognition of respiratory syncytial virus infection

Respiratory syncytial virus (RSV) is the leading cause of respiratory infection in infants and young children. Severe clinical manifestation of RSV infection is a bronchiolitis, which is common in infants under six months of age. Recently, RSV has been recognized as an important cause of respiratory infection in older populations with cardiovascular morbidity or immunocompromised patients. Howe...